Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response
June 1 (Reuters) - Arcus Biosciences Inc RCUS.N:
INITIAL DATA FROM THE ARC-20 STUDY OF CASDATIFAN PLUS CABOZANTINIB SHOWED NEARLY HALF OF PATIENTS WITH METASTATIC KIDNEY CANCER HAD A CONFIRMED RESPONSE
ARCUS BIOSCIENCES INC - ARC-20 STUDY SHOWS 46% RESPONSE RATE IN METASTATIC KIDNEY CANCER
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.